An2 Therapeutics, INC Form 4 insider transactions

Joseph S Zakrzewski, a Director of AN2 Therapeutics, Inc., reported a transaction in 405,880 shares of common stock on August 14, 2026.

AN2 Therapeutics Director Aziz Kabeer acquired 2,852 shares of common stock as compensation, increasing his indirect holdings.

Gilbert Lynn Marks, a Director at AN2 Therapeutics, Inc., acquired 2,789 shares of common stock on July 10, 2026, issued in lieu of cash compensation.

Patricia A. Martin, a Director at AN2 Therapeutics, Inc., acquired 766 shares of common stock on July 10, 2026, as part of her compensation.

AN2 Therapeutics COO and Chief Legal Officer Joshua M. Eizen reported a sale of 5,945 shares of common stock on July 8, 2026, to cover tax withholding obligations.

Sarah Joanne Williams, Principal Accounting Officer at AN2 Therapeutics, Inc., reported a sale of 265 common shares to cover tax withholding obligations related to vesting Restricted Stock Units.

AN2 Therapeutics, Inc. reports a Form 4 filing detailing share acquisition by Director Aziz Kabeer.

Gilbert Lynn Marks, a Director at AN2 Therapeutics, Inc., acquired 3,775 shares of common stock as compensation, increasing his beneficial ownership.

Patricia A. Martin, a Director at AN2 Therapeutics, Inc., acquired 1,192 shares of common stock on April 10, 2026, as part of her compensation.

AN2 Therapeutics' Chief Financial Officer, Lucy Day, had 221,965 stock options repriced to an exercise price of $3.91 per share.

AN2 Therapeutics' Chief Development Officer, Sanjay Chanda, had a significant portion of his stock options repriced to a lower exercise price of $3.91 per share.

AN2 Therapeutics' Director Gilbert Lynn Marks had 44,769 stock options repriced to $3.91 per share, contingent on future events.

AN2 Therapeutics director Kabeer Aziz repriced 44,466 stock options to an exercise price of $3.91 per share, subject to certain conditions.

AN2 Therapeutics' director, Patricia A. Martin, had her stock options repriced to a lower exercise price of $3.91 per share, subject to certain conditions.

AN2 Therapeutics Director Margaret M. FitzPatrick repriced 45,567 stock options to an exercise price of $3.91 per share, effective March 19, 2026.

AN2 Therapeutics director Stephanie Wong's stock options for 59,103 shares were repriced to $3.91 per share on March 19, 2026.

AN2 Therapeutics Director Joseph S. Zakrzewski repriced over 134,000 stock options to a lower exercise price of $3.91 per share.

AN2 Therapeutics repriced stock options for COO and Chief Legal Officer Joshua M. Eizen, lowering exercise prices to $3.91 per share.

AN2 Therapeutics director Melvin K. Spigelman's stock options were repriced to $3.91 per share, reflecting the closing price on March 19, 2026.

AN2 Therapeutics director Robin Shane Readnour's stock options were repriced to $3.91 per share, subject to specific conditions.

AN2 Therapeutics' CEO Eric Easom had 742,649 stock options repriced to $3.91 per share, significantly lower than their original grant prices, to restore incentive value.

AN2 Therapeutics' Principal Accounting Officer, Sarah Joanne Williams, sold 327 shares of common stock to cover tax withholding obligations.

Joshua M. Eizen, AN2 Therapeutics' Chief Operating and Legal Officer, reported the acquisition of 50,000 restricted stock units and 100,000 stock options, alongside existing equity holdings.

AN2 Therapeutics' CFO, Lucy Day, reported the acquisition of 38,000 restricted stock units and 77,000 stock options, increasing her beneficial ownership.

AN2 Therapeutics' Principal Accounting Officer, Sarah Joanne Williams, received a grant of 48,375 restricted stock units and reported sales of shares for tax obligations and on the open market.

AN2 Therapeutics CEO Eric Easom was granted 112,250 restricted stock units and 224,500 stock options, effective February 20, 2026.

AN2 Therapeutics' Chief Development Officer, Sanjay Chanda, was granted 38,000 restricted stock units and options to purchase 77,000 shares.

AN2 Therapeutics Director Gilbert Lynn Marks was granted 20,400 stock options with a vesting date of February 20, 2027.

AN2 Therapeutics, Inc. Director Robin Shane Readnour was granted 20,400 stock options with an exercise price of $1.04, vesting in February 2027.

AN2 Therapeutics Director Stephanie Wong was granted 20,400 stock options with an exercise price of $1.04, vesting on February 20, 2027.